CCCC
C4 Therapeutics, Inc.
Key Financials
Operating Income
$-115222000
↑ 3.7%
EPS (Diluted)
$-1.27
↑ 16.4%
Total Assets
$359.1M
↑ 2.7%
Total Liabilities
$102.5M
↓ 23.3%
Shareholders' Equity
$256.6M
↑ 18.8%
Cash & Equivalents
$74.6M
↑ 34.4%
Long-term Debt
$0.00
↓ 100.0%
Net Income
$-104994000
↑ 0.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/10/2026 | View on SEC |
| 8-K | 4/9/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 144 | 3/9/2026 | View on SEC |
| S-8 | 2/26/2026 | View on SEC |
| 10-K | 2/26/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| 4 | 2/18/2026 | View on SEC |
| 4 | 2/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CCCC |
| Company Name | C4 Therapeutics, Inc. |
| CIK | 1662579 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617) 231-0700 |